Established criteria for disease controlling drugs in ankylosing spondylitis.
Gladman
D D
DD
Centre for Prognosis Studies, Toronto Western Hospital, ECW 5-034B, Toronto, ON, Canada. dafna.gladman@utoronto.ca
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha